BrainXell Unveils Groundbreaking Sensory Neurons for Neuroscience Research BrainXell has launched a new platform of human iPSC-derived sensory neurons, enabling advanced research in pain biology and neuroscience.

BrainXell Unveils Groundbreaking Sensory Neurons for Neuroscience Research #United_States #Madison #iPSC #BrainXell #sensory_neurons

BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting BrainXell is set to showcase innovative findings on iPSC-derived therapies for Parkinson's Disease, focusing on BXT-110 during the 2025 SfN meeting in San Diego.

BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting #United_States #San_Diego #iPSC_therapy #BrainXell #BXT-110

BrainXell Therapeutics Announces Promising Preclinical Study Results for iPSC-Derived Neuronal Therapy in Parkinson’s Disease BrainXell Therapeutics has revealed groundbreaking preclinical results for BXT-110, an iPSC-derived therapy targeting Parkinson's disease, showing significant promise for future treatments.

BrainXell Therapeutics Announces Promising Preclinical Study Results for iPSC-Derived Neuronal Therapy in Parkinson’s Disease #USA #San_Diego #Parkinson's #BrainXell #BXT-110

BrainXell Enhances Leadership with New Appointments to Drive Innovation BrainXell announces the appointment of Paul Marcus and Dr. Su-Chun Zhang to its executive team, highlighting their commitment to advancing neuroscience and therapeutic solutions.

BrainXell Enhances Leadership with New Appointments to Drive Innovation #USA #Madison #BrainXell #Paul_Marcus #Dr._Su-Chun_Zhang

BrainXell, Inc. Welcomes Katherine Vega Stultz as New CEO and Board Director Katherine Vega Stultz is appointed CEO and board director of BrainXell, Inc., revolutionizing neuroscience with innovative therapies.

BrainXell, Inc. Welcomes Katherine Vega Stultz as New CEO and Board Director #USA #Madison #CEO #BrainXell #Katherine_Vega_Stultz